These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28181957)

  • 1. Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report.
    Martín-Blanco A; Patrizi B; Soler J; Gasol X; Elices M; Gasol M; Carmona C; Pascual JC
    Int Clin Psychopharmacol; 2017 Jul; 32(4):231-234. PubMed ID: 28181957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
    Di Nicola M; De Filippis S; Martinotti G; De Risio L; Pettorruso M; De Persis S; Maremmani AGI; Maremmani I; di Giannantonio M; Janiri L
    Adv Ther; 2017 Jul; 34(7):1636-1649. PubMed ID: 28540656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders.
    Ralevski E; Ball S; Nich C; Limoncelli D; Petrakis I
    Am J Addict; 2007; 16(6):443-9. PubMed ID: 18058408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptoms of anxiety, depression, and borderline personality in alcohol use disorder with and without comorbid substance use disorder.
    Howe LK; Fisher LR; Atkinson EA; Finn PR
    Alcohol; 2021 Feb; 90():19-25. PubMed ID: 33232791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study.
    Rolland B; Valin T; Langlois C; Auffret M; Gautier S; Deheul S; Danel T; Bordet R; Cottencin O
    Int Clin Psychopharmacol; 2015 Jan; 30(1):49-53. PubMed ID: 25356633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K; Bladström A; Torup L; Gual A; van den Brink W
    Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.
    Bohus MJ; Landwehrmeyer GB; Stiglmayr CE; Limberger MF; Böhme R; Schmahl CG
    J Clin Psychiatry; 1999 Sep; 60(9):598-603. PubMed ID: 10520978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A; He Y; Torup L; van den Brink W; Mann K;
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.
    van den Brink W; Aubin HJ; Bladström A; Torup L; Gual A; Mann K
    Alcohol Alcohol; 2013; 48(5):570-8. PubMed ID: 23873853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Borderline Personality Disorder With Versus Without Alcohol Use Disorder: Comparing Impulsivity and Schema Modes.
    Boog M; Dugonjic H; Arntz A; Goudriaan AE; Wetering BJMVD; Franken IHA
    J Pers Disord; 2022 Feb; 36(1):1-18. PubMed ID: 33999655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients.
    Timäus C; Meiser M; Wiltfang J; Bandelow B; Wedekind D
    Hum Psychopharmacol; 2021 Nov; 36(6):e2800. PubMed ID: 34029405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
    van den Brink W; Sørensen P; Torup L; Mann K; Gual A;
    J Psychopharmacol; 2014 Aug; 28(8):733-44. PubMed ID: 24671340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
    Yéléhé-Okouma M; Martini H; Lemarié J; Labroca P; Petitpain N; Gibaja V; Paille F; Gillet P
    Fundam Clin Pharmacol; 2017 Oct; 31(5):574-579. PubMed ID: 28322465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M
    Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Temperament and character in persons with borderline personality disorder].
    Barnow S; Rüge J; Spitzer C; Freyberger HJ
    Nervenarzt; 2005 Jul; 76(7):839-40, 842-4, 846-8. PubMed ID: 15448917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
    Mueller S; Luderer M; Zhang D; Meulien D; Brach BS; Schou MB
    Alcohol Alcohol; 2020 Feb; 55(1):63-70. PubMed ID: 31713583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.